Loading...
Market
What will be the efficacy rate of the Russian mRNA cancer vaccine by the end of 2025?
2
Resolution / Starting Odds
Above 90% efficacy • 25%
80-90% efficacy • 25%
70-79% efficacy • 25%
Below 70% efficacy • 25%
Clinical trial results published in scientific journals or official reports from the Russian Ministry of Health.
Story
Russia to Launch Free Personalized mRNA Cancer Vaccine Targeting Neoantigens in 2025
Dec 28, 2024, 08:02 AM
Russian scientists have developed a personalized mRNA vaccine aimed at treating cancer, with plans to launch it in early 2025. The vaccine, which will be free for Russian citizens, is designed to train the immune system to recognize and target cancer cells by identifying mutations called neoantigens. The development involves the National Medical Research Centre of the Russian Ministry of Health and the Gamaleya National Research Center of Epidemiology, the latter known for its work on the Sputnik V vaccine. The vaccine is expected to cost the state 300,000 rubles per dose, targeting cancers such as melanoma, lung, gastrointestinal, and possibly kidney cancers. This breakthrough comes amidst ongoing geopolitical tensions, highlighting Russia's focus on advancing medical research.
View original story
Similar markets
10,000 to 50,000 • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%
Less than 10,000 • 25%
More than 100,000 • 25%
10,000 to 50,000 • 25%
Less than 10,000 • 25%
50,001 to 100,000 • 25%
Yes • 50%
No • 50%
100,000 to 199,999 doses • 25%
300,000 or more doses • 25%
200,000 to 299,999 doses • 25%
Less than 100,000 doses • 25%
No Major Approval • 25%
EU Approval • 25%
US FDA Approval • 25%
WHO Approval • 25%
10,000 to 50,000 • 25%
More than 100,000 • 25%
50,001 to 100,000 • 25%
Less than 10,000 • 25%
Trials delayed • 25%
Successful with no major issues • 25%
Successful with minor issues • 25%
Unsuccessful • 25%
